Suitable for use to measure free Ustekinumab in patient samples.
Recommended antibody pair for pharmacokinetic (PK) bridging assay to measure free drug: CABT-ZB258 - CABT-ZB259
Recommended Working Concentration: 0.05-1 μg/ml
Summary
Specifications
Antibody Isotype
IgG1, κ
Clone
0B6
Immunogen
Ustekinumab
Conjugate
Unconjugated
Applications
Application Notes
Suitable for use in PK bridging ELISA. We recommend the following for sandwich ELISA (Capture - Detection): CABT-ZB258 - CABT-ZB259 Recommended Working Concentration: 0.05-1 μg/ml
General Notes
We recommend the following antibody pair to develop a pharmacokinetic (PK) bridging assay to measure free drug: CABT-ZB258 - CABT-ZB259 CABT-ZB258 is recommended for use as a capture antibody when paired with CABT-ZB259 as a detection antibody. Ustekinumab with trade name Stelara, is an FDA-approved drug to Crohn's disease, Ulcerative Colitis, Plaque Psoriasis and Psoriatic Arthritis, targeting both interleukins (IL)-12 and IL-23. Ustekinumab is a fully human immunoglobulin G1 kappa mAb that binds to IL-12 and IL-23. Ustekinumab binds to the p40 subunit common to IL-12 and IL-23 and prevents their interaction with the IL-12 receptor β1 subunit of the IL-12 and IL-23 receptor complexes, thereby disrupting the proinflammatory pathway.
Target
Alternative Names
Mouse monoclonal antibody to Ustekinumab/Stelara; CNTO 1275; Stelara; Ustekinumab
Citations
Publication ()
Have you cited CABT-ZB258 in a publication? Let us know and earn a reward for your research.
My Review for Mouse Anti-Ustekinumab monoclonal antibody, clone 0B6
Creative Diagnostics products are for RESEARCH USE ONLY, please make sure your review is research based.
Required fields are marked with *
Terms and conditions:
We will select high-quality review customers and offer a $30 coupon for your next purchase.
All product reviews must be submitted in the English language.
Creative Diagnostics will not share any personal information of applicants, and all information will be treated with strict confidentiality and will not be sold or disclosed to a third party.
COA
Publication 
Loading ......
